Comparison of in vitro activities of plazomicin and other aminoglycosides against clinical isolates of Klebsiella pneumoniae and Escherichia coli
| Autor: | Hale Gümüş, Aylin Üsküdar Güçlü, Çiğdem Erol, Gizem İnce, Ahmet Başustaoğlu, Hasan Cenk Mirza |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
Klebsiella pneumoniae Microbial Sensitivity Tests Plazomicin medicine.disease_cause beta-Lactamases Microbiology chemistry.chemical_compound Escherichia coli polycyclic compounds medicine Pharmacology (medical) Carbapenem resistance Pharmacology Gradient Diffusion Method biology biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification In vitro Anti-Bacterial Agents Aminoglycosides Infectious Diseases chemistry Amikacin Sisomicin Gentamicin medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 76:3192-3196 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/dkab331 |
| Popis: | Objectives To compare the in vitro activity of plazomicin and two older aminoglycosides (gentamicin and amikacin) against 180 isolates of Escherichia coli and Klebsiella pneumoniae, including subsets of 60 non-ESBL-producing, 60 ESBL-producing and 60 carbapenem-resistant (46 carrying blaOXA-48, 11 carrying blaNDM and 3 carrying blaOXA-48 and blaNDM) strains. Methods MICs of plazomicin, gentamicin and amikacin were determined by a gradient diffusion method. Gentamicin and amikacin MICs were interpreted according to CLSI criteria and EUCAST breakpoint tables. Plazomicin MICs were interpreted using FDA-defined breakpoints. Results All non-ESBL-producing and ESBL-producing isolates were susceptible to plazomicin. The plazomicin susceptibility rate (71.7%) in carbapenem-resistant isolates was significantly higher than those observed for gentamicin (45%) and amikacin (56.7% and 51.7% according to CLSI and EUCAST breakpoints, respectively). Gentamicin, amikacin and plazomicin susceptibility rates (35.6% for gentamicin; 44.4% and 37.8% for amikacin according to CLSI and EUCAST breakpoints, respectively; 64.4% for plazomicin) in carbapenem-resistant K. pneumoniae were significantly lower than those observed for carbapenem-resistant E. coli isolates (73.3% for gentamicin; 93.3% for amikacin and plazomicin). Gentamicin, amikacin and plazomicin susceptibility rates for blaNDM-positive isolates were lower than those observed for blaOXA-48-positive isolates, but differences were not statistically significant. Among the isolates that were non-susceptible to both gentamicin and amikacin, the plazomicin susceptibility rate was less than 30%. Conclusions Although plazomicin showed excellent in vitro activity against carbapenem-susceptible isolates, the plazomicin resistance rate increased to 35.6% among carbapenem-resistant K. pneumoniae and further increased to 45.5% among blaNDM-positive isolates. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|